Summary
Compliance is at the forefront of pharma companies' minds today. Companies face the threat of staggering fines and increased scrutiny from regulatory bodies. A growing level of public distrust of the industry also carries a negative effect on companies' reputations. These events have created a new regulatory environment that has dramatically affected companies' organizational structures and practices. In fact, the industry's most influential companies have reexamined-and sometimes reinvented-the way they do business.
This new landscape thrusts compliance groups into the center of the action. Compliance teams have gained additional resources and a stronger tie to executive leadership. But with this increased power comes challenges in communicating regulatory changes, in training and testing employees, and in ensuring compliance across an organization.
This report examines the current state of compliance management at some of the pharmaceutical industry's top companies. It looks at metrics and strategies surrounding three aspects of compliance success:
- Structure, Headcounts and Investment - Provides up-to-date structuring strategies, headcounts and investments of top compliance groups
- Monitoring and Ensuring Compliance - Details companies' strategies regarding monitoring, training, testing, documentation, firewalls, and much more
- Activities and Challenges - Examines the focus and reach of top compliance functions. Also looks at the impact and reactions to some recent regulations. Finally, survey respondents rate the challenges facing compliance efforts moving forward.
|
